Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TauroLock-Hep100 for prevention of central line-associated bloodstream infection in pediatric oncology
NL-OMON55586Phase 4Active, not recruiting
- Sponsor
- KWF Kankerbestrijding
- Start
- Oct 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in central line-associated bloodstream infection (CLABSI) and Phlebothrombosis comparing TauroLock-Hep100 arm with Heparin lock control arm (2 arms). Primary endpoint: Incidence of first central line-associated bloodstream infection. Started Oct 2020; status: active, not recruiting.
02
Drugs
TauroLock-HEP100heparin
03
Conditions
central line-associated bloodstream infection (CLABSI)Phlebothrombosis
Beyond the preview
Go deeper on NL-OMON55586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55586.